Daniel Månsson

Daniel Månsson, Chief Clinical Officer and founder of Flow Neuroscience, shares insights into the world of transcranial direct current stimulation (tDCS) as an innovative therapy for major depressive disorder. He discusses the promising safety profile of tDCS, comparing its efficacy to traditional antidepressants. Månsson also highlights the rigorous trials that validated its effectiveness and the potential of Flow's treatment as a first-line option for mild to moderate depression. Additionally, he explores the future of personalized mental health interventions.